Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 1.00 |
| ▸ | FNTB | P49356 | 19/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 4/20 | 1.00 |
| ▸ | NRAS | P01111 | 1/20 | 0.47 |
| ▸ | HRAS | P01112 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445627 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL31472029 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL445938 | 0.94 | FNTA (0.88) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL445940 | 0.94 | FNTA (0.88) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL9083203 | 0.93 | FNTA (0.87) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL9083210 | 0.93 | FNTA (0.87) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL9082830 | 0.92 | FNTA (0.84) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL9082833 | 0.92 | FNTA (0.84) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL3499541 | 0.90 | FNTA (0.82) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL3499539 | 0.90 | FNTA (0.82) | FNTAFNTBPGGT1BNRASHRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-1744751-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-01-24 | — | — | EP | claimed |
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | claimed |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | claimed |
| WO-2005089502-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | claimed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | claimed |
| EP-0906099-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0906099-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | claimed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | claimed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | claimed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | claimed |
| CN-108289922-B | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210205389-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | CHANG GUNG MEDICAL FOUND KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-07-08 | — | — | US | disclosed |
| US-10953059-B2 | Methods and compositions for treating non-small cell lung cancer | CHANG GUNG MEDICAL FOUNDATION KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-03-23 | — | — | US | disclosed |
| EP-0952842-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
| WO-1997038664-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | FNTA 4/4885FNTB 19/4885PGGT1B 274/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885 |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | SNCA, PARK7, NLN | FNTA 12/4885FNTB 44/4885PGGT1B 1996/4885 |
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | FNTA 1/4885FNTB 12/4885PGGT1B 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.